DeepMed Research

Ferrer Internacional S.A.

🇨🇱Chile

Country: 🇨🇱Chile

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

Not yet recruiting

Conditions: Persistent Pulmonary Hypertension of Newborn

First Posted Date: 2024-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 60

Registration Number: NCT06499363

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Phase 2

Recruiting

Conditions: Progressive Supranuclear Palsy

Interventions: Drug: Placebo
Drug: FNP-223

First Posted Date: 2024-04-09

Last Posted Date: 2025-05-06

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 220

Registration Number: NCT06355531

Locations: 🇬🇧
University of Cambridge, Cambridge, United Kingdom
🇺🇸
The Neurology Center of Southern California - Carlsbad, Carlsbad, California, United States
🇺🇸
UCSF Weill Institute for Neurosciences, San Francisco, California, United States

and more 39 locations

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: FAB122

First Posted Date: 2023-05-19

Last Posted Date: 2025-03-04

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 201

Registration Number: NCT05866926

Locations: 🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Conditions: Pulmonary Hypertension
Interstitial Lung Disease
Combined Pulmonary Fibrosis and Emphysema

First Posted Date: 2022-10-10

Last Posted Date: 2022-10-10

Lead Sponsor: Ferrer Internacional S.A.

Registration Number: NCT05572996

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: FAB122
Drug: Placebo

First Posted Date: 2022-01-05

Last Posted Date: 2025-03-18

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 300

Registration Number: NCT05178810

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇫🇷
CHU Nice, Nice, France
🇫🇷
Hôpital de la Salpêtrière, Paris, France

and more 35 locations

Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)

Phase 3

Completed

Conditions: Diarrhea

Interventions: Combination Product: placebo + ORS + Zinc supplementation
Combination Product: Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation

First Posted Date: 2019-08-22

Last Posted Date: 2020-11-04

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 150

Registration Number: NCT04065529

Locations: 🇸🇳
Niakhar Center IRD, Dakar, Senegal

Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury

Phase 1

Conditions: Acute Traumatic Spinal Cord Injury

Interventions: Drug: FAB117-HC
Other: Control group

First Posted Date: 2016-09-28

Last Posted Date: 2021-09-16

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 48

Registration Number: NCT02917291

Locations: 🇪🇸
Complexo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain

and more 6 locations

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Phase 2

Conditions: Hypertension

Interventions: Drug: Cardiovascular Fixed Dose Combination Pill AAR
Drug: Ramipril 10 mg
Drug: Atorvastatin 40 mg

First Posted Date: 2016-06-07

Last Posted Date: 2017-04-10

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 528

Registration Number: NCT02791958

Locations: 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸
Meridien Research, St. Petersburg, Florida, United States
🇺🇸
Diagnostics Research Group, San Antonio, Texas, United States

and more 32 locations

Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting

Phase 4

Completed

Conditions: Agitation

Interventions: Device: Staccato® Delivery System Loxapine (ADASUVE®)

First Posted Date: 2015-08-18

Last Posted Date: 2020-11-04

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 323

Registration Number: NCT02525991

Locations: 🇪🇸
Ferrer Internacional S.A., Barcelona, Spain

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Phase 3

Completed

Conditions: Impetigo

Interventions: Drug: Placebo
Drug: Ozenoxacin

First Posted Date: 2014-03-18

Last Posted Date: 2024-08-20

Lead Sponsor: Ferrer Internacional S.A.

Target Recruit Count: 412

Registration Number: NCT02090764

Locations: 🇵🇷
Caparra Internal Medicine Center, Rio Grande, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy